{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:16:36Z","timestamp":1782890196023,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38583-8","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:06:33Z","timestamp":1770329193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mesoporous silicon microparticles enhance antiviral immunity and memory responses against SARS-CoV-2"],"prefix":"10.1038","volume":"16","author":[{"given":"Ana","family":"L\u00f3pez-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Real-Ar\u00e9valo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Mayol-Hornero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana Ausio","family":"Cendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Laxalde-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Nogales-Altozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benigno","family":"Rivas-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Amor\u00f3s-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mart\u00edn-Adrados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Mart\u00ednez-Del-Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal J.","family":"Mart\u00edn-Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mart\u00ednez-Naves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel G\u00f3mez","family":"del Moral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"38583_CR1","doi-asserted-by":"publisher","first-page":"1043109","DOI":"10.3389\/fimmu.2023.1043109","volume":"14","author":"SK Verma","year":"2023","unstructured":"Verma, S. K. et al. New-age vaccine adjuvants, their development, and future perspective. Front. Immunol. 14, 1043109. https:\/\/doi.org\/10.3389\/fimmu.2023.1043109 (2023).","journal-title":"Front. Immunol."},{"key":"38583_CR2","doi-asserted-by":"publisher","unstructured":"Pulendran, B., Arunachalam, P. S. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants., Nat. Rev. Drug Discov., 20\u00a0(6), 454\u2013475 (2021). https:\/\/doi.org\/10.1038\/s41573-021-00163-y","DOI":"10.1038\/s41573-021-00163-y"},{"key":"38583_CR3","doi-asserted-by":"publisher","unstructured":"Audran, R. et al. Mar., Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro., Vaccine, 21(11\u201312), 1250\u20131255 (2003). https:\/\/doi.org\/10.1016\/s0264-410x(02)00521-2","DOI":"10.1016\/s0264-410x(02)00521-2"},{"key":"38583_CR4","doi-asserted-by":"publisher","unstructured":"Langer, R., Cleland, J. L. & Hanes, J. New advances in microsphere-based single-dose vaccines., Adv. Drug Deliv. Rev., 28(1), 97\u2013119 (1997). https:\/\/doi.org\/10.1016\/s0169-409x(97)00053-7","DOI":"10.1016\/s0169-409x(97)00053-7"},{"key":"38583_CR5","doi-asserted-by":"publisher","unstructured":"Jim\u00e9nez-Peri\u00e1\u00f1ez, A. et al. Mesoporous silicon microparticles enhance MHC class i cross-antigen presentation by human dendritic cells. Clin. Dev. Immunol. 2013 https:\/\/doi.org\/10.1155\/2013\/362163 (2013).","DOI":"10.1155\/2013\/362163"},{"key":"38583_CR6","doi-asserted-by":"publisher","unstructured":"Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J. & Peiffer-Smadja, N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review., Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis., 28(2), 202\u2013221 (2022). https:\/\/doi.org\/10.1016\/j.cmi.2021.10.005","DOI":"10.1016\/j.cmi.2021.10.005"},{"key":"38583_CR7","doi-asserted-by":"publisher","unstructured":"Doria-Rose, N. et al. Jun., Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.,\u00a0N. Engl. J. Med., 384(23), 2259\u20132261 (2021). (United States)\u00a0https:\/\/doi.org\/10.1056\/NEJMc2103916","DOI":"10.1056\/NEJMc2103916"},{"key":"38583_CR8","doi-asserted-by":"publisher","unstructured":"Barouch, D. H. et al. Sep., Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.,\u00a0N. Engl. J. Med., 385(10), 951\u2013953 (2021). (United States)\u00a0https:\/\/doi.org\/10.1056\/NEJMc2108829","DOI":"10.1056\/NEJMc2108829"},{"key":"38583_CR9","doi-asserted-by":"publisher","unstructured":"Yang, L. T. et al. Aug., Long-lived effector\/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients., Clin. Immunol., 120(2), 171\u2013178 (2006). https:\/\/doi.org\/10.1016\/j.clim.2006.05.002","DOI":"10.1016\/j.clim.2006.05.002"},{"key":"38583_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/bs.aivir.2016.08.003","volume":"96","author":"L Enjuanes","year":"2016","unstructured":"Enjuanes, L. et al. Molecular basis of coronavirus virulence and vaccine development. Adv. Virus Res. 96, 245\u2013286. https:\/\/doi.org\/10.1016\/bs.aivir.2016.08.003 (2016).","journal-title":"Adv. Virus Res."},{"key":"38583_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12026-014-8534-z","volume":"59","author":"R Channappanavar","year":"2014","unstructured":"Channappanavar, R., Zhao, J. & Perlman, S. T cell-mediated immune response to respiratory coronaviruses. Immunol. Res. 59, 1\u20133. https:\/\/doi.org\/10.1007\/s12026-014-8534-z (2014).","journal-title":"Immunol. Res."},{"key":"38583_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-1-0716-3239-0_8","volume":"2673","author":"A L\u00f3pez-Gomez","year":"2023","unstructured":"L\u00f3pez-Gomez, A., Real-Ar\u00e9valo, I., Mart\u00edn-Palma, R., Mart\u00ednez-Naves, E. & Del Moral, M. G. Manufacture of mesoporous silicon microparticles (MSMPs) as adjuvants for vaccine delivery. Methods Mol. Biol. 2673, 123\u2013130. https:\/\/doi.org\/10.1007\/978-1-0716-3239-0_8 (2023).","journal-title":"Methods Mol. Biol."},{"key":"38583_CR13","doi-asserted-by":"publisher","first-page":"1023255","DOI":"10.3389\/fimmu.2022.1023255","volume":"13","author":"PJ Alcolea","year":"2022","unstructured":"Alcolea, P. J. et al. Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2. Front. Immunol. 13, 1023255. https:\/\/doi.org\/10.3389\/fimmu.2022.1023255 (2022).","journal-title":"Front. Immunol."},{"key":"38583_CR14","doi-asserted-by":"publisher","unstructured":"Navarro-Tovar, G., Rocha-Garc\u00eda, D., Wong-Arce, A., Palestino, G. & Rosales-Mendoza, S. Mesoporous silicon particles favor the induction of long-lived humoral responses in mice to a peptide-based vaccine. Mater. (Basel). 11 (7). https:\/\/doi.org\/10.3390\/ma11071083 (2018).","DOI":"10.3390\/ma11071083"},{"key":"38583_CR15","doi-asserted-by":"publisher","unstructured":"Castillo, R. R. et al. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update., Expert Opin. Drug Deliv.,\u00a016(4), 415\u2013439 (2019). https:\/\/doi.org\/10.1080\/17425247.2019.1598375","DOI":"10.1080\/17425247.2019.1598375"},{"key":"38583_CR16","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1021\/jacs.6b12622","volume":"139","author":"PL Abbaraju","year":"2017","unstructured":"Abbaraju, P. L. et al. Asymmetric Silica Nanoparticles with Tunable Head-Tail Structures Enhance Hemocompatibility and Maturation of Immune Cells. J. Am. Chem. Soc. 139, 6321\u20136328. https:\/\/doi.org\/10.1021\/jacs.6b12622 (2017).","journal-title":"J. Am. Chem. Soc."},{"key":"38583_CR17","doi-asserted-by":"publisher","unstructured":"Yan, J. et al. Porous silicon and silica carriers for delivery of peptide therapeutics., Drug Deliv. Transl. Res., 14(12), 3549\u20133567 (2024). https:\/\/doi.org\/10.1007\/s13346-024-01609-7","DOI":"10.1007\/s13346-024-01609-7"},{"key":"38583_CR18","doi-asserted-by":"publisher","unstructured":"Abbaraju, P. L. et al. Asymmetric mesoporous silica nanoparticles as potent and safe immunoadjuvants provoke high immune responses., Chem. Commun. (Camb)., 54(16), 2020\u20132023 (2018). https:\/\/doi.org\/10.1039\/c8cc00327k","DOI":"10.1039\/c8cc00327k"},{"key":"38583_CR19","doi-asserted-by":"publisher","unstructured":"Janeway, C. A. J. Approaching the asymptote? Evolution and revolution in immunology., Cold Spring Harb. Symp. Quant. Biol., 54(1), 1\u201313 (1989). https:\/\/doi.org\/10.1101\/sqb.1989.054.01.003","DOI":"10.1101\/sqb.1989.054.01.003"},{"key":"38583_CR20","doi-asserted-by":"publisher","first-page":"113920","DOI":"10.1016\/j.colsurfb.2024.113920","volume":"238","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. Size effect of mesoporous silica nanoparticles on regulating the immune effect of oral influenza split vaccine. Colloids Surf. B Biointerfaces 238, 113920. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.113920 (2024).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"38583_CR21","doi-asserted-by":"publisher","first-page":"101529","DOI":"10.1016\/j.eclinm.2022.101529","volume":"50","author":"J Garc\u00eda-P\u00e9rez","year":"2022","unstructured":"Garc\u00eda-P\u00e9rez, J. et al. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S\/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. EClinicalMedicine 50, 101529. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101529 (2022).","journal-title":"EClinicalMedicine"},{"key":"38583_CR22","doi-asserted-by":"publisher","unstructured":"Lin, Q., Zhu, L., Ni, Z., Meng, H. & You, L. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection., Journal of microbiology, immunology, and infection\u2009=\u2009Wei mian yu gan ran za zhi, 53 (5), 821\u2013822 (2020). (England)\u00a0https:\/\/doi.org\/10.1016\/j.jmii.2020.03.015","DOI":"10.1016\/j.jmii.2020.03.015"},{"key":"38583_CR23","doi-asserted-by":"publisher","unstructured":"Flaxman, A. et al. Sep., Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)., Lancet (London, England), 398 (10304), 981\u2013990 (2021). https:\/\/doi.org\/10.1016\/S0140-6736(21)01699-8","DOI":"10.1016\/S0140-6736(21)01699-8"},{"key":"38583_CR24","doi-asserted-by":"publisher","unstructured":"Nazeri, S., Zakeri, S., Mehrizi, A. A., Sardari, S. & Djadid, N. D. Measuring of IgG2c isotype instead of IgG2a in immunized C57BL\/6 mice with plasmodium Vivax TRAP as a subunit vaccine candidate in order to correct interpretation of Th1 versus Th2 immune response. Exp. Parasitol. 216 https:\/\/doi.org\/10.1016\/J.EXPPARA.2020.107944 (Sep. 2020).","DOI":"10.1016\/J.EXPPARA.2020.107944"},{"key":"38583_CR25","doi-asserted-by":"publisher","unstructured":"Adam, A. et al. Nov., A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine., Transl. Res., 249, 13\u201327 (2022). https:\/\/doi.org\/10.1016\/j.trsl.2022.06.004","DOI":"10.1016\/j.trsl.2022.06.004"},{"issue":"7839","key":"38583_CR26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/S41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588(7839), 682. https:\/\/doi.org\/10.1038\/S41586-020-2852-1 (2020).","journal-title":"Nature"},{"key":"38583_CR27","doi-asserted-by":"publisher","unstructured":"Li, H. et al. The abundant distribution and duplication of SARS-CoV-2 in the cerebrum and lungs promote a high mortality rate in Transgenic hACE2-C57 mice. Int. J. Mol. Sci. 25 (2). https:\/\/doi.org\/10.3390\/ijms25020997 (2024).","DOI":"10.3390\/ijms25020997"},{"issue":"5","key":"38583_CR28","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/J.CELL.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr, T. N. et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell 182(5), 1295\u20131310. https:\/\/doi.org\/10.1016\/J.CELL.2020.08.012 (2020) (.e20).","journal-title":"Cell"},{"issue":"6","key":"38583_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/S41422-021-00496-8","volume":"31","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. Cell. Res. 31(6), 720\u2013722. https:\/\/doi.org\/10.1038\/S41422-021-00496-8 (2021).","journal-title":"Cell. Res."},{"key":"38583_CR30","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Arriaza, J. et al. Mar., COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice, J. Virol., 95(7), (2021). https:\/\/doi.org\/10.1128\/JVI.02260-20","DOI":"10.1128\/JVI.02260-20"},{"issue":"2","key":"38583_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","volume":"11","author":"P He","year":"2015","unstructured":"He, P., Zou, Y. & Hu, Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum. Vaccin Immunother. 11 (2), 477. https:\/\/doi.org\/10.1080\/21645515.2014.1004026 (2015).","journal-title":"Hum. Vaccin Immunother"},{"issue":"11","key":"38583_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.22159\/ijpps.2016v8i11.14311","volume":"8","author":"SA Hudu","year":"2016","unstructured":"Hudu, S. A., Shinkafi, S. H. & Umar, S. An overview of Recombinant vaccine technology, adjuvants and vaccine delivery methods. Int. J. Pharm. Pharm. Sci. 8 (11), 19\u201324. https:\/\/doi.org\/10.22159\/ijpps.2016v8i11.14311 (2016).","journal-title":"Int. J. Pharm. Pharm. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38583-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38583-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38583-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:37:17Z","timestamp":1771591037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38583-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38583"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38583-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Universidad Complutense of Madrid and Comunidad of Madrid (Dec 14\/2022\/PROEX 272.5\/22).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"7355"}}